Genital Diseases, Female  >>  Recentin (cediranib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recentin (cediranib) / AstraZeneca
NCT00275028: AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed
2
47
US
cediranib maleate, AZD2171, Recentin
National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Stage I Ovarian Epithelial Cancer, Stage II Ovarian Epithelial Cancer
03/10
01/11
NCT00278343: Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Completed
2
74
Canada, US
cediranib maleate, AZD2171, Recentin, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
06/10
01/18
CRUK-C-2009-01, NCT01229930 / 2009-011542-25: Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
130
Europe
carboplatin, cediranib maleate, paclitaxel, laboratory biomarker analysis, pharmacological study, quality-of-life assessment
University of Glasgow
Cervical Cancer
12/12
12/12
NCT02340611: A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Completed
2
4
Canada
Olaparib, AZD2281, KU-0059436, Cediranib, AZD2171, Recentin™
University Health Network, Toronto, AstraZeneca
Ovarian Cancer
06/18
06/18

Download Options